|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Rosen David B. 4 TRI HARBOR COURT PORT WASHINGTON, NY 11050 |
Sr. V.P. - Rising Pharma |
/s/ David B. Rosen | 02/22/2012 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | On December 31, 2010, Sun Acquisition Corp. ("Sun"), a wholly-owned subsidiary of Aceto Corporation ("Aceto"), purchased substantially all of the assets of Rising Pharmaceuticals, Inc. (now known as Pearl Ventures Inc.) ("Rising") pursuant to that certain asset purchase agreement ("Purchase Agreement") entered into by and among Aceto, Rising and the stockholders of Rising - Ronald Gold and the Reporting Person. As contemplated by the Purchase Agreement, a portion of the purchase price included the issuance of 1,000,000 shares of Aceto common stock to Rising (the "Consideration Shares"). Rising has distributed all of the Consideration Shares to its stockholders, including 200,000 shares to the Reporting Person. The Reporting Person previously reported indirect ownership of the Consideration Shares to the extent of his pecuniary interest therein. This Report reflects a change in the form of beneficial ownership only. |